Slide 1: Cover letter to stock exchanges
RPG LIFE SCIENCES LIMITED L Regd. Off.: RPG House 463, Dr. Annie Besant Road Worli, Mumbai 400030, India Tel: +91-22-24981650 / 66606375 Fax:+91-22-24970127 Email: info@rpglifesciences.com RPO LIFE SCIENCES www.rpglifesciences.com CIN : L24232MH2007PLC169354 May 02, 2023 To The Manager BSE Limited L
Slide 2: Investors' Presentation FY23
RPG LIFE SCIENCES An ~>>R,::.c:; Company Investors’ Presentation FY23
Slide 3: Disclaimer
Disclaimer This presentation may include statements which may constitute forward-looking statements. All statements that address expectations or projections about the future, including, but not limited to, statements about the strategy for growth, business development, market position, expenditures,
Slide 4: RPG Group: One of India's fastest-growing diversified conglomerates
RPG Group: One of India's fastest-growing diversified conglomerates UN -EA,SHTALENT RPG Group has a business history dating back to 1820 AD in banking, textiles, jute, and tea. RPG Enterprises was founded in 1979 and currently operates in various businesses TOUCH LIVES in Infrastructure, Technology,
Slide 5: An Integrated Pharmaceutical Company – APIs to Formulations
RPG Life Sciences: An Integrated Pharmaceutical Company –APIs to Formulations; R&D to Manufacturing to Marketing RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global
Slide 6: RPG Life Sciences Product Portfolio
RPG Life Sciences Product Portfolio: Strong ‘Textbook’ brands being augmented by Diligent Life Cycle Management and New Launches in Chronic and Specialty therapies Key Therapies Key Products Legacy Portfolio New Portfolio Nephrology Immunosuppressants Text Book Brands Specialty Chronic Life Cycle Ma
Slide 7: Financial Performance
Financial Performance An <l>» RPCi Company 6 L R?G LIFE SCIENCES
Slide 8: FY23: A Milestone Year
FY23: A Milestone Year First time ever 500 Cr+ Revenues 100 Cr+ EBITDA 100 Cr+ Cash in Hand 1000 Cr+ Market Cap An <l>» RPCi Company L R?G LIFE SCIENCES
Slide 9: Journey of RPG Life Sciences
Journey of RPG Life Sciences 1 2 Process Excellence Product Portfolio, People, Business Processes Fundamentals Fixation Sales Hygiene, People, Organization 3 Sustainable Profitable Growth Revenues, Volumes, Margins 4 Benchmark 5 Performance Profitability, Leverage, Liquidity Ratios Scale-up An <l>»
Slide 10: The Journey So Far: Fundamentals Fixation to Benchmark Performance
The Journey So Far: Fundamentals Fixation to Benchmark Performance Fundamentals Process Sustainable Benchmark Performance Fixation* Excellence* Profitable Growth* (= or <1000 cr Sales Cos*) Business Hygiene Product Portfolio ↑ Revenues Profitability Ratios • 3-year New Product Grid • Revenue: 330.2
Slide 11: The Journey Ahead: Benchmark Performance to Scale-up
The Journey Ahead: Benchmark Performance to Scale-up 7 Pillars Identified 1 2 3 4 5 6 7 State-of-art Targeted Lead Therapy Talent Institutionalized TECHNOLOGY ↑ Capacity Niche- focus M&As ADJACENT Development INNOVATION enablement PLANTS R&D PIPELINE Spaces /Acquisition • Focused New • Institutional
Slide 12: Revenues, PBT, Cashflows: A Trajectory of Strong y-o-y Growth
Revenues, PBT, Cashflows: A Trajectory of Strong y-o-y Growth ↑ Revenues ↑ PBT ↑ Cashflows ↑ EPS Rs. Crores Rs. Crores Rs. Crores Rs 512.8 115.2 91.7 40.9 440.2 389.1 73.2 31.1 375.6 70.3 330.2 24.2 53.6 17.5 41.8 40.3 6.5 15.1 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY
Slide 13: Margins: A Trajectory of y-o-y Expansion despite Market Challenges
Margins: A Trajectory of y-o-y Expansion despite Market Challenges EBITDA Margin :10.4% (FY19) to 21.0% (FY23);PBT Margin: 4.6% (FY19) to 17.9% (FY23); PAT Margin: 3.3% (FY19) to 13.2% (FY23) EBITDA% 20.3% 21.0% 18.2% PBT% 15.9% 16.6% 17.9% 13.8% PAT% 11.7% 13.2% 11.1% 11.1% 10.4% 10.3% 9.8% 9.3% 8.
Slide 14: Key Ratios (ROCE, ROE, D/E): A Trajectory of y-o-y uptrend
Key Ratios (ROCE, ROE, D/E) : A Trajectory of y-o-y uptrend _f ROCE% _f ROE% Debt/Equity Ratio - -l 22.0% 0.22 27.9% 29.1% 18.5% 20.1% 23.6% 24.3% 16.4% 11.0% 6.7% 0.06 0.01 FY19 FY20 FY21 FY22 FY23 FY19 FY20 FY21 FY22 FY23 FY19 FY20 - FY21 0.00 FY22 0.00 FY23 Company continues to remain Debt-free A
Slide 15: Q4 FY23: Yet Another Strong Quarter
Q4 FY23 : Yet Another Strong Quarter (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin ---t 13.8 17.8 10.9 118.5 103.8 14.8 ~ 11.7% Q4 FY22 Q4 FY23 [] 14.2% Q4 FY22 •15.0% Q4 FY23 10.5% Q4 FY22 Q4 FY23 PAT & PAT Margin EPS - -t -t 10.4 6.3
Slide 16: Full Year FY23: Yet Another Strong Year of Performance
Full Year FY23 : Yet Another Strong Year of Performance (All figures in Rs. Crores except EPS in Rs.) Revenue from Operations EBITDA & EBITDA Margin PBT & PBT Margin - --t - --t - -t 512.8 91.7 107.5 73.2 440.2 89.4 21.0% 17.9% 20.3% 16.6% FY22 FY23 FY22 FY23 FY22 FY23 PAT & PAT Margin EPS - -t -t 6
Slide 17: Business Segment-wise Performance: FY23
Business Segment-wise Performance: FY23 337.1 • Domestic Formulations contributed 67% to total sales of FY23 Domestic • 20% sales growth majorly driven by legacy products 280.9 Formulations • Better than market growth (DF) • New products* contribution improving consistently (currently >20%) on accou
Slide 18: RPG Life Sciences ICRA Rating Reaffirmed in FY23
RPG Life Sciences ICRA Rating Reaffirmed in FY23 Long term rating reaffirmed at A Short term rating reaffirmed at A1 Outlook on long term rating has been retained as Stable The rating reaffirmation factors: Strong brands in the Indian Pharmaceutical Industry Considerable improvement in the opera
Slide 19: Business Strategy
Business Strategy An <l>» RPCi Company 18 L R?G LIFE SCIENCES
Slide 20: Domestic Formulations (DF)
Domestic Formulations (DF) • Operating in Mass/Mass-specialty and Specialty segments • Presence in both Acute & Chronic therapy areas • Leading Text Book Brands – Azoran, Aldactone, Lomotil, Naprosyn, Serenace, Norpace • Leading player in Immunosuppressant category • Good Customer Coverage - Cardiol
Slide 21: Diligent implementation of Business Strategy is yielding results
Diligent implementation of Business Strategy is yielding results Product portfolio Strategic brand assets Customer coverage Sales force effectiveness Profitability rejuvenation building deepening augmentation improvement *New Product Contribution Naprosyn+ becomes Expansion of Target Monthly Revenue
Slide 22: International Formulations (IF) Business: Overview and Strategy
International Formulations (IF) Business: Overview and Strategy • Strong presence in immunosuppressant segment (Azathioprine) • Footprints across Regulated and Emerging Markets - Canada, UK, Germany, France, Australia, South East Asia, Africa • Long lasting, impeccable supply track record and busine
Slide 23: APIs Business: Business Strategy and Way Forward
APIs Business: Business Strategy and Way Forward • High value, low volume, niche APIs • Footprints across geographies - LATAM, Germany, China, South • Mature stable molecules Korea, Iran, Bangladesh, Egypt, India, etc. • Provides backward integration to International • Strong customer focus – long-l
Slide 24: Infrastructure & Backend Capabilities
Infrastructure & Backend Capabilities An <l>» RPCi Company 23 L R?G LIFE SCIENCES
Slide 25: Manufacturing Facilities
Manufacturing Facilities Formulations Unit 1, Ankleshwar • F1 unit caters to the domestic and emerging markets • Multipurpose plant with dedicated product lines for oral dosage forms including tablets, liquids and powder • WHO, Kenya, Nigeria approved Formulations Unit 2, Ankleshwar • F2 unit caters
Slide 26: Strong Backend Capabilities
Strong Backend Capabilities Quality Regulatory • All critical SOPs harmonized through CQA • Well established & evolved Regulatory function catering • Quarterly internal audit of all plants by CQA to Canada, UK, EU, Australia and emerging markets • All critical deviations, change controls and market
Slide 27: Operational Highlights
Operational Highlights An <l>» RPCi Company 26 L R?G LIFE SCIENCES
Slide 28: Top Operational Highlights
Top 10 Operational Highlights Comprehensive Life Cycle Management Strategy for DF 1 Legacy Product Naprosyn becomes the first 50 Cr+ Brand of the Company Legacy products yielding results New Product portfolio across identified segments The New Product Denosumab Sales ~5 Cr in the very first year of
Slide 29: Digitalization Initiatives to Transform Business
Digitalization Initiatives to Transform Business Game Changer Customer Connect Initiative Employee Connect Initiatives Digital Platform for comprehensive ~ 2 .0 Salesforce Operations tracking: #Customer visits, customer engagement activities, sales performance analytics etc .- • Anytime, Anywhere Do
Slide 30: Digitalization Initiatives to Transform Business
Digitalization Initiatives to Transform Business Digital Retina Intelligent Chilling IOT based AHU Power Management Scanner Plant Manager monitoring system System • Biometric Access • Implementation • Operates Pumps • Safe, reliable, with IRIS/ Retina of Utility Asset & Chillers efficient, and Scann
Slide 31: People Initiatives to build Performance Culture with focus on Happiness
People Initiatives to build Performance Culture with focus on Happiness I Love My Work I Feel Valued RPGLS Heroes I am Growing ~ Outperformance ~ recognition We Skill. You Grow. Competency building You Excel. We Applaud. continuum Motivation continuum •• Akanksha High 0 Career development Happiness
Slide 32: Initiatives for building a Performance Driven Culture: Glimpses
Initiatives for building a Performance Driven Culture: Glimpses Skilling Rewards & Recognition Employee engagement: Parivar Tyohar Utsav Employee Connect Idea Generation An <l>» RPCi Company
Slide 33: Awards & Recognitions
Awards & Recognitions An <l>» RPCi Company 32 L R?G LIFE SCIENCES
Slide 34: Jamnalal Bajaj Award for Fair Business Practices
RPG Life Sciences Awarded with ‘Jamnalal Bajaj Award for Fair Business Practices’ Jamnalal Bajaj Award for Fair Business Practices (2021-22) An <l>» RPCi Company L R?G LIFE SCIENCES
Slide 35: RPG Life Sciences Bagged Top Awards from IDMA
RPG Life Sciences Bagged Top Awards from IDMA Industry Recognition to RPG Life Sciences Best Patent Award Best Corporate Citizen Award An <l>» RPCi Company L R?G LIFE SCIENCES
Slide 36: Committed to our Transformation Agenda to continue our upward growth trajectory
We are Committed to our Transformation Agenda to continue our upward growth trajectory Profit Growth and Focus on Revenue Growth Strong Governance Cashflows Building Domestic Formulations Business Continued diligent thrust on cost All operations within the via the identified 5 Pillars control measur
Slide 37: Thank You
T H A N K Y O U An <l>» RPCi Company L R?G LIFE SCIENCES